| Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net M Girschikofsky, M Arico, D Castillo, A Chu, C Doberauer, J Fichter, ... Orphanet journal of rare diseases 8, 1-11, 2013 | 409 | 2013 |
| Clinical features of 24 patients with rebound‐associated vertebral fractures after denosumab discontinuation: systematic review and additional cases AD Anastasilakis, SA Polyzos, P Makras, B Aubry‐Rozier, S Kaouri, ... Journal of Bone and Mineral Research 32 (6), 1291-1296, 2017 | 327 | 2017 |
| Irisin in metabolic diseases SA Polyzos, AD Anastasilakis, ZA Efstathiadou, P Makras, N Perakakis, ... Endocrine 59, 260-274, 2018 | 263 | 2018 |
| Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues GA Kaltsas, D Papadogias, P Makras, AB Grossman Endocrine-related cancer 12 (4), 683-699, 2005 | 226 | 2005 |
| Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 … AD Anastasilakis, SA Polyzos, P Makras, A Gkiomisi, I Bisbinas, ... Osteoporosis International 25, 1633-1642, 2014 | 153 | 2014 |
| Endocrine manifestations in Langerhans cell histiocytosis P Makras, KI Alexandraki, GP Chrousos, AB Grossman, GA Kaltsas Trends in Endocrinology & Metabolism 18 (6), 252-257, 2007 | 129 | 2007 |
| Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2‐year clinical trial AD Anastasilakis, SE Papapoulos, SA Polyzos, NM Appelman‐Dijkstra, ... Journal of Bone and Mineral Research 34 (12), 2220-2228, 2019 | 127 | 2019 |
| Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis AD Anastasilakis, SA Polyzos, P Makras European journal of endocrinology 179 (1), R31-R45, 2018 | 123 | 2018 |
| Denosumab discontinuation and the rebound phenomenon: a narrative review AD Anastasilakis, P Makras, MP Yavropoulou, G Tabacco, AM Naciu, ... Journal of clinical medicine 10 (1), 152, 2021 | 119 | 2021 |
| International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults G Goyal, A Tazi, RS Go, KL Rech, JL Picarsic, R Vassallo, JR Young, ... Blood, The Journal of the American Society of Hematology 139 (17), 2601-2621, 2022 | 111 | 2022 |
| Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab AD Anastasilakis, KA Toulis, SA Polyzos, CD Anastasilakis, P Makras Therapeutics and Clinical Risk Management, 295-306, 2012 | 106 | 2012 |
| Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and … P Hadji, N Papaioannou, E Gielen, M Feudjo Tepie, E Zhang, I Frieling, ... Osteoporosis International 26, 2479-2489, 2015 | 103 | 2015 |
| Novel therapies for osteoporosis P Makras, S Delaroudis, AD Anastasilakis Metabolism 64 (10), 1199-1214, 2015 | 97 | 2015 |
| Expression of microRNAs that regulate bone turnover in the serum of postmenopausal women with low bone mass and vertebral fractures MP Yavropoulou, AD Anastasilakis, P Makras, DG Tsalikakis, ... European Journal of Endocrinology 176 (2), 169-176, 2017 | 95 | 2017 |
| Multiple clinical vertebral fractures following denosumab discontinuation AD Anastasilakis, P Makras Osteoporosis International 27, 1929-1930, 2016 | 93 | 2016 |
| High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas GP Piaditis, GA Kaltsas, II Androulakis, A Gouli, P Makras, D Papadogias, ... Clinical endocrinology 71 (6), 772-778, 2009 | 93 | 2009 |
| Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly GA Kaltsas, II Androulakis, K Tziveriotis, D Papadogias, A Tsikini, ... Clinical endocrinology 67 (6), 917-922, 2007 | 86 | 2007 |
| Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment AD Anastasilakis, MP Yavropoulou, P Makras, GT Sakellariou, ... European journal of endocrinology 176 (6), 677-683, 2017 | 82 | 2017 |
| Medical treatment of hypercalcaemia P Makras, SE Papapoulos Hormones 8, 83-95, 2009 | 81 | 2009 |
| Skeletal diseases in Cushing’s syndrome: osteoporosis versus arthropathy G Kaltsas, P Makras Neuroendocrinology 92 (Suppl. 1), 60-64, 2010 | 78 | 2010 |
Gregory KaltsasProfessor in General Medicine - Endocrinology, National and Kapodistrian University of Athens在 med.uoa.gr 的电子邮件经过验证
Gregory KaltsasProfessor in General Medicine - Endocrinology, National and Kapodistrian University of Athens在 med.uoa.gr 的电子邮件经过验证